263 related articles for article (PubMed ID: 31237441)
1. Clinical implications of mismatch repair deficiency in prostate cancer.
Sedhom R; Antonarakis ES
Future Oncol; 2019 Jul; 15(20):2395-2411. PubMed ID: 31237441
[TBL] [Abstract][Full Text] [Related]
2. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer.
Sena LA; Fountain J; Isaacsson Velho P; Lim SJ; Wang H; Nizialek E; Rathi N; Nussenzveig R; Maughan BL; Velez MG; Ashkar R; Larson AC; Pritchard CC; Adra N; Bryce AH; Agarwal N; Pardoll DM; Eshleman JR; Lotan TL; Antonarakis ES
Oncologist; 2021 Feb; 26(2):e270-e278. PubMed ID: 33215787
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Abida W; Cheng ML; Armenia J; Middha S; Autio KA; Vargas HA; Rathkopf D; Morris MJ; Danila DC; Slovin SF; Carbone E; Barnett ES; Hullings M; Hechtman JF; Zehir A; Shia J; Jonsson P; Stadler ZK; Srinivasan P; Laudone VP; Reuter V; Wolchok JD; Socci ND; Taylor BS; Berger MF; Kantoff PW; Sawyers CL; Schultz N; Solit DB; Gopalan A; Scher HI
JAMA Oncol; 2019 Apr; 5(4):471-478. PubMed ID: 30589920
[TBL] [Abstract][Full Text] [Related]
4. Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene Mutations.
Antonarakis ES; Shaukat F; Isaacsson Velho P; Kaur H; Shenderov E; Pardoll DM; Lotan TL
Eur Urol; 2019 Mar; 75(3):378-382. PubMed ID: 30337059
[TBL] [Abstract][Full Text] [Related]
5. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
6. Biologics, Immunotherapy, and Future Directions in the Treatment of Advanced Cholangiocarcinoma.
Saeed A; Park R; Al-Jumayli M; Al-Rajabi R; Sun W
Clin Colorectal Cancer; 2019 Jun; 18(2):81-90. PubMed ID: 30905548
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of mismatch repair genes mutations and clinical activity of PD-1 therapy in Chinese prostate cancer patients.
Fang B; Wei Y; Zeng H; Li Y; Chen S; Zhang T; Pan J; Wang B; Wu J; Jin S; Gan H; Hu M; Zhang D; Ye D; Zhu Y
Cancer Immunol Immunother; 2023 Jun; 72(6):1541-1551. PubMed ID: 36522531
[TBL] [Abstract][Full Text] [Related]
8. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
[TBL] [Abstract][Full Text] [Related]
9. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
[TBL] [Abstract][Full Text] [Related]
10. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
11. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
Graham LS; Montgomery B; Cheng HH; Yu EY; Nelson PS; Pritchard C; Erickson S; Alva A; Schweizer MT
PLoS One; 2020; 15(5):e0233260. PubMed ID: 32453797
[TBL] [Abstract][Full Text] [Related]
12. Predictive Biomarkers for Checkpoint Blockade in Urothelial Cancer: A Systematic Review.
Lavoie JM; Black PC; Eigl BJ
J Urol; 2019 Jul; 202(1):49-56. PubMed ID: 30730407
[TBL] [Abstract][Full Text] [Related]
13. Loss of DNA mismatch repair proteins in prostate cancer.
Sharma M; Yang Z; Miyamoto H
Medicine (Baltimore); 2020 May; 99(19):e20124. PubMed ID: 32384491
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair deficiency assessment by immunohistochemistry: for Lynch syndrome screening and beyond.
Wong HL; Christie M; Gately L; Tie J; Lee B; Semira C; Lok SW; Wong R; Gibbs P
Future Oncol; 2018 Nov; 14(26):2725-2739. PubMed ID: 30004261
[TBL] [Abstract][Full Text] [Related]
15. Histopathological and genetic features of mismatch repair-deficient high-grade prostate cancer.
Wyvekens N; Tsai HK; Sholl LM; Tucci J; Giannico GA; Gordetsky JB; Hirsch MS; Barletta JA; Acosta AM
Histopathology; 2022 Jun; 80(7):1050-1060. PubMed ID: 35395112
[TBL] [Abstract][Full Text] [Related]
16. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
Latham A; Srinivasan P; Kemel Y; Shia J; Bandlamudi C; Mandelker D; Middha S; Hechtman J; Zehir A; Dubard-Gault M; Tran C; Stewart C; Sheehan M; Penson A; DeLair D; Yaeger R; Vijai J; Mukherjee S; Galle J; Dickson MA; Janjigian Y; O'Reilly EM; Segal N; Saltz LB; Reidy-Lagunes D; Varghese AM; Bajorin D; Carlo MI; Cadoo K; Walsh MF; Weiser M; Aguilar JG; Klimstra DS; Diaz LA; Baselga J; Zhang L; Ladanyi M; Hyman DM; Solit DB; Robson ME; Taylor BS; Offit K; Berger MF; Stadler ZK
J Clin Oncol; 2019 Feb; 37(4):286-295. PubMed ID: 30376427
[TBL] [Abstract][Full Text] [Related]
17. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W; Rashed S; Hube-Magg C; Kluth M; Simon R; Büscheck F; Clauditz TS; Grupp K; Minner S; Tsourlakis MC; Möller-Koop C; Graefen M; Adam M; Haese A; Wittmer C; Sauter G; Izbicki JR; Huland H; Schlomm T; Steurer S; Krech T; Lebok P
Carcinogenesis; 2017 Jan; 38(1):19-27. PubMed ID: 27803051
[TBL] [Abstract][Full Text] [Related]
18. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA.
Barata P; Agarwal N; Nussenzveig R; Gerendash B; Jaeger E; Hatton W; Ledet E; Lewis B; Layton J; Babiker H; Bryce A; Garje R; Stein C; Kiedrowski L; Saylor P; Sartor O
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32788235
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of mismatch repair deficiency in prostate cancers diagnosed in mismatch repair gene mutation carriers from the colon cancer family registry.
Rosty C; Walsh MD; Lindor NM; Thibodeau SN; Mundt E; Gallinger S; Aronson M; Pollett A; Baron JA; Pearson S; Clendenning M; Walters RJ; Nagler BN; Crawford WJ; Young JP; Winship I; Win AK; Hopper JL; Jenkins MA; Buchanan DD
Fam Cancer; 2014 Dec; 13(4):573-82. PubMed ID: 25117503
[TBL] [Abstract][Full Text] [Related]
20. Genetic Testing in Prostate Cancer.
Sokolova AO; Cheng HH
Curr Oncol Rep; 2020 Jan; 22(1):5. PubMed ID: 31974718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
